Similar articles for PMID: 30909618

Year	Number of Results
2010	2
2011	1
2012	2
2013	2
2014	4
2015	5
2016	19
2017	12
2018	7
2019	12
2020	18
2021	11
2022	12
2023	6
2024	0

1

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.

Madariaga A, Lheureux S, Oza AM. Madariaga A, et al. Cancers (Basel). 2019 Mar 23;11(3):416. doi: 10.3390/cancers11030416. Cancers (Basel). 2019. PMID: 30909618 Free PMC article. Review.

2

Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.

Parkes EE, Kennedy RD. Parkes EE, et al. Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28. Oncologist. 2016. PMID: 27022037 Free PMC article. Review.

3

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.

Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V. Gadducci A, et al. J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6. J Ovarian Res. 2019. PMID: 30691488 Free PMC article. Review.

4

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.

Papa A, Caruso D, Strudel M, Tomao S, Tomao F. Papa A, et al. J Transl Med. 2016 Sep 15;14:267. doi: 10.1186/s12967-016-1027-1. J Transl Med. 2016. PMID: 27634150 Free PMC article. Review.

5

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.

Le Page C, Amuzu S, Rahimi K, Gotlieb W, Ragoussis J, Tonin PN. Le Page C, et al. Semin Cancer Biol. 2021 Dec;77:110-126. doi: 10.1016/j.semcancer.2020.08.005. Epub 2020 Aug 19. Semin Cancer Biol. 2021. PMID: 32827632 Review.

6

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.

McMullen M, Karakasis K, Madariaga A, Oza AM. McMullen M, et al. Cancers (Basel). 2020 Jun 17;12(6):1607. doi: 10.3390/cancers12061607. Cancers (Basel). 2020. PMID: 32560564 Free PMC article. Review.

7

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.

Wiedemeyer WR, Beach JA, Karlan BY. Wiedemeyer WR, et al. Front Oncol. 2014 Mar 3;4:34. doi: 10.3389/fonc.2014.00034. eCollection 2014. Front Oncol. 2014. PMID: 24624361 Free PMC article. Review.

8

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.

Tobalina L, Armenia J, Irving E, O'Connor MJ, Forment JV. Tobalina L, et al. Ann Oncol. 2021 Jan;32(1):103-112. doi: 10.1016/j.annonc.2020.10.470. Epub 2020 Oct 19. Ann Oncol. 2021. PMID: 33091561 Free article.

9

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB. Hennessy BT, et al. J Clin Oncol. 2010 Aug 1;28(22):3570-6. doi: 10.1200/JCO.2009.27.2997. Epub 2010 Jul 6. J Clin Oncol. 2010. PMID: 20606085 Free PMC article.

10

Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.

Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J. Tattersall A, et al. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. Cochrane Database Syst Rev. 2022. PMID: 35170751 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year